Autres langues Collegium Pharmaceutical, Inc.

Actions

COLL

US19459J1043

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 18:30:23 29/07/2026			Varia. 5j.	Varia. 1 janv.
36,47 ^USD	+1,59%		+5,29%	-21,05%

20/07	Collegium Pharmaceutical va transférer son siège social à One Lincoln, à Boston	MT
15/05	Collegium Pharmaceutical, Inc. annonce la nomination de Michael Donovan au poste d'administrateur	CI

Autres langues

23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
20/07	Collegium Pharmaceutical to Relocate HQ to One Lincoln in Boston
20/07	Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
05/06	Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/05	Collegium to Participate in 2026 Jefferies Global Healthcare Conference
15/05	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director
12/05	Collegium completes acquisition of Azstarys® from Corium Therapeutics
12/05	Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance
12/05	Collegium Pharmaceutical, Inc. Announces Executive Changes
12/05	Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05	Collegium Pharmaceutical, Inc. completed the acquisition of AZSTARYS Business of Corium, LLC.
07/05	Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Collegium Pharmaceutical : COLL Q1 2026 Earnings Presentation (Pre-Close) FINAL 05-05-26
07/05	(COLL) Collegium Pharmaceutical Expects 2026 Net Product Revenue Range $805M - $825M
07/05	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Reports Q1 Revenue $193.5M, vs. FactSet Est of $184.5M
07/05	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q1 Adjusted EPS $1.76 per Share, vs. FactSet Est of $1.52
07/05	Collegium Pharmaceutical: Q1 Earnings Snapshot
07/05	Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on July 7, 2025.
07/05	Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
07/05	Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for Full Year 2026
23/04	Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
08/04	Collegium to Participate in Upcoming Investor Conferences
08/04	Collegium to Participate in Upcoming Investor Conferences
07/04	Collegium Pharmaceutical, Inc. Announces Current Member of the Board John Fallon Not to Stand for Re-Election At the Annual Meeting